cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2017-32-2-26-30cardiotomsk-293Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL STUDIESКЛИНИЧЕСКОЕ ЗНАЧЕНИЕ СЫВОРОТОЧНОЙ ТИМИДИНКИНАЗЫ ПРИ ХРОНИЧЕСКОМ ЛИМФОЛЕЙКОЗЕCLINICAL SIGNIFICANCE OF SERUM THYMIDINE KINASE IN CHRONIC LYMPHOCYTIC LEUKEMIAЗагоскинаТ. П.ZagoskinaT. P.

канд. мед. наук, доцент кафедры госпитальной терапии ФГБОУ ВО “Кировский государственный медицинский университет” Минздрава России

Адрес: 610998, г. Киров, ул. Карла Маркса, 112

zagoskina@blood.kirov.ruЗотинаЕ. Н.ZotinaE. N.

канд. мед. наук, младший научный сотрудник научно-клинического отдела  ФГБУН “Кировский НИИ гематологии и переливания крови” ФМБА России

Адрес: 610027, г. Киров, ул. Красноармейская, 72

enzotina@mail.ruШардаковВ. И.ShardakovV. I.

докт. мед. наук, профессор, руководитель лаборатории иммунологии лейкозов  ФГБУН “Кировский НИИ гематологии и переливания крови” ФМБА России

Адрес: 610027, г. Киров, ул. Красноармейская, 72

КрюковаМ. Г.KryukovaM. G.

канд. мед. наук, научный сотрудник лаборатории иммунологии лейкозов ФГБУН  “Кировский НИИ гематологии и переливания крови” ФМБА России

Адрес: 610027, г. Киров, ул. Красноармейская, 72

ФГБОУ ВО “Кировский государственный медицинский университет” Минздрава РоссииРоссияKirov State Medical UniversityRussian FederationФГБУН “Кировский НИИ гематологии и переливания крови” ФМБА РоссииРоссияKirov Research Institute of Hematology and Blood TransfusionRussian Federation2017061020173222630Copyright © Загоскина Т.П., Зотина Е.Н., Шардаков В.И., Крюкова М.Г., 20172017Загоскина Т.П., Зотина Е.Н., Шардаков В.И., Крюкова М.Г.Zagoskina T.P., Zotina E.N., Shardakov V.I., Kryukova M.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/293

Изучено содержание тимидинкиназы в сыворотке крови у 229 больных хроническим лимфолейкозом (ХЛЛ) в зависимости от особенностей клинического течения заболевания. Установлено, что у больных ХЛЛ концентрация тимидинкиназы коррелирует со стадией заболевания, индолентным или прогрессирующим вариантом течения опухолевого процесса, периодом ремиссии и рецидивом. Определение концентрации тимидинкиназы в сыворотке крови у больных в момент постановки диагноза дает дополнительную информацию для прогнозирования выживаемости, свободной от лечения, ответа на терапию и общей выживаемости больных ХЛЛ.

The content of serum thymidine kinase in 229 patients with chronic lymphocytic leukemia (CLL), depending on the clinical course of the disease was studied. It was found that patients with CLL thymidine kinase has such a concentration which correlates with disease stage, indolent or progressive variants of the tumor process, a period of remission and relapse. Determination of thymidine kinase concentrations in patients’ serum at diagnosis provides an additional information for the prediction of survival, free from treatment, treatment response and overall survival of patients with CLL.

хронический лимфолейкозсывороточная тимидинкиназапрогнозвыживаемостьchronic lymphocytic leukemiaserum thymidine kinaseprognosissurvivalReferencesHallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment // Am. J. Hematol. – 2013. – Vol. 88 (9). – P. 803-816.Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment // Am. J. Hematol. – 2013. – Vol. 88 (9). – P. 803-816.Stilgenbauer S., Hallek M. Chronic lymphocytic leukemia. Treatment and genetic risk profile // Internist (Berl). – 2013. – Vol. 54 (2). – P. 166-170.Stilgenbauer S., Hallek M. Chronic lymphocytic leukemia. Treatment and genetic risk profile // Internist (Berl). – 2013. – Vol. 54 (2). – P. 166-170.Al-Madhoun A.S., Tjarks W., Eriksson S. The role of thymidine kinases in the activation of pyrimidine nucleoside analogues // Mini Rev. Med. Chem. – 2004. – Vol. 4 (4). – P. 341–350.Al-Madhoun A.S., Tjarks W., Eriksson S. The role of thymidine kinases in the activation of pyrimidine nucleoside analogues // Mini Rev. Med. Chem. – 2004. – Vol. 4 (4). – P. 341–350.Hu C.M., Chang Z.F. Mitotic control of dTTP pool: a necessity or coincidence? // J. Biomed. Sci. – 2007. – Vol. 14 (4). – P. 491–497.Hu C.M., Chang Z.F. Mitotic control of dTTP pool: a necessity or coincidence? // J. Biomed. Sci. – 2007. – Vol. 14 (4). – P. 491–497.Aufderklamm S., Todenhцfer T., Gakis G. et al. Thymidine kinase and cancer monitoring // Cancer Lett. – 2012. – Vol. 316 (1). – P. 6–10.Aufderklamm S., Todenhцfer T., Gakis G. et al. Thymidine kinase and cancer monitoring // Cancer Lett. – 2012. – Vol. 316 (1). – P. 6–10.Matthews С., Catherwood M.A., Morris T.C. et al. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression // Eur. J. Haematol. – 2006. – Vol. 77 (4). – P. 309–317.Matthews С., Catherwood M.A., Morris T.C. et al. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression // Eur. J. Haematol. – 2006. – Vol. 77 (4). – P. 309–317.Chen Y., Ying M., Chen Y. et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings // Int. J. Clin. Oncol. – 2010. – Vol. 15 (4). – P. 359–368.Chen Y., Ying M., Chen Y. et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings // Int. J. Clin. Oncol. – 2010. – Vol. 15 (4). – P. 359–368.Pan Z.L., Ji X.Y., Shi Y.M. et al. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients // J. Cancer Res. Clin. Oncol. – 2010. – Vol. 136 (8). – P. 1193–1199.Pan Z.L., Ji X.Y., Shi Y.M. et al. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients // J. Cancer Res. Clin. Oncol. – 2010. – Vol. 136 (8). – P. 1193–1199.He E., Xu X.H., Guan H. et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin’s lymphoma // Nucleosides Nucleotides Nucleic. Acids. – 2010. – Vol. 29 (4–6). – P. 352–358.He E., Xu X.H., Guan H. et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin’s lymphoma // Nucleosides Nucleotides Nucleic. Acids. – 2010. – Vol. 29 (4–6). – P. 352–358.Konoplev S.N., Fritsche H.A., O’Brien S. et al. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia // Am. J. Clin. Pathol. – 2010. – Vol. 134 (3). – P. 472–477.Konoplev S.N., Fritsche H.A., O’Brien S. et al. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia // Am. J. Clin. Pathol. – 2010. – Vol. 134 (3). – P. 472–477.Di Raimondo F., Giustolisi R., Lerner S. et al. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine // Ann. Oncol. – 2001. – Vol. 12 (5). – P. 621–625.Di Raimondo F., Giustolisi R., Lerner S. et al. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine // Ann. Oncol. – 2001. – Vol. 12 (5). – P. 621–625.Xu W., Cao X., Miao K.R. et al. Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors // Int. J. Hematol. – 2009. – Vol. 90 (2). – P. 205–211.Xu W., Cao X., Miao K.R. et al. Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors // Int. J. Hematol. – 2009. – Vol. 90 (2). – P. 205–211.Molica S., Giannarelli D., Mirabelli R. et al. Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model // Eur. J. Haematol. – 2016. – Vol. 96 (1). – P. 72–77.Molica S., Giannarelli D., Mirabelli R. et al. Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model // Eur. J. Haematol. – 2016. – Vol. 96 (1). – P. 72–77.Binet J.L., Auquier A, Dighiero G. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis // Cancer. – 1981. – Vol. 48 (1). – P. 198–206.Binet J.L., Auquier A, Dighiero G. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis // Cancer. – 1981. – Vol. 48 (1). – P. 198–206.Hallek M., Cheson B.D., Catovsky D. et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute– Working Group 1996 guidelines // Blood. – 2008. – Vol. 111 (12). – P. 5446–5456.Hallek M., Cheson B.D., Catovsky D. et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute– Working Group 1996 guidelines // Blood. – 2008. – Vol. 111 (12). – P. 5446–5456.

The authors declare that there are no conflicts of interest present.